Doptelet (avatrombopag) / SOBI 
Welcome,         Profile    Billing    Logout  
 31 Diseases   42 Trials   42 Trials   576 News 


12345678»
  • ||||||||||  Nplate (romiplostim) / Amgen, Kyowa Kirin, Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis
    Review, Journal:  Tapering and Sustained Remission of Thrombopoietin Receptor Agonists (TPO-RAs): Is it Time for Paediatric ITP? (Pubmed Central) -  Aug 20, 2024   
    The issue of tapering and discontinuation of TPO-RAs in paediatric patients with ITP has received little attention to date. Given that paediatric ITP has much higher rates of spontaneous remission than ITP in adults, we consider that the possibility of SROT of TPO-RAs in paediatric patients with ITP is a neglected but very relevant issue in this subtype of the disease.
  • ||||||||||  Journal:  Update on the Use of Thrombopoietin-Receptor Agonists in Pediatrics. (Pubmed Central) -  Aug 17, 2024   
    Current developments include testing of avatrombopag and lusutrombopag that are approved for the treatment of thrombocytopenia associated with chronic liver disease (CLD) in adult patients. In pediatric and adolescent medicine, we expect in the near future a broader use of TPO-RAs as first-line treatment in primary ITP, thereby considering immunomodulatory effects that increase the rate of sustained remission off-treatment, and a selective use in rare inherited thrombocytopenias based on current clinical trials.
  • ||||||||||  Doptelet (avatrombopag) / SOBI
    Efficacy and safety of avatrombopag in the treatment of thrombocytopenia after umbilical cord blood transplantation (Ballroom B3) -  May 17, 2024 - Abstract #ISTH2024ISTH_2015;    
    Fifty-two patients were given avatrombopag within 30 days post-UCBT, and the treatment was continued for more than 7 days to promote platelet engraftment (avatrombopag group); the other 13 patients were given avatrombopag for secondary failure of platelet recovery (SFPR group). The median time to platelet engraftment was shorter in the avatrombopag group than in the control group (32.5 vs. 38 days, P = 0.036).
  • ||||||||||  Doptelet (avatrombopag) / SOBI
    Immune Thrombocytopenia treated with Avatrombopag in a Kidney Transplant Recipient (Exhibition Hall) -  May 17, 2024 - Abstract #ISTH2024ISTH_1326;    
    This was on a background of renal transplantation for which he remained significantly immunosuppressed with prednisone and tacrolimus. The sudden onset thrombocytopenia initially occurred in the setting of a severe COVID-19 infection with a superimposed bacterial/fungal pneumonia and CMV viraemia.
  • ||||||||||  Doptelet (avatrombopag) / SOBI
    Real-life multicenter experience with the use of Avatrombopag (Exhibition Hall) -  May 17, 2024 - Abstract #ISTH2024ISTH_1318;    
    The median number of previous lines of treatment for patients was 2.29 (1-8). All patients diagnosed with ITP had previously received corticosteroids, and 42% had received another TPO-RA previously.
  • ||||||||||  Nplate (romiplostim) / Amgen, Kyowa Kirin, Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis
    Management of Chronic ITP with TPO-mimetics- Single Centre Experience at Birmingham Children (Exhibition Hall) -  May 17, 2024 - Abstract #ISTH2024ISTH_1289;    
    In the eltrombopag cohort (23 females, 17 males), 2 children exhibited no response. Among the 38 responders, 9 experienced a loss of response, while 6 successfully discontinued eltrombopag and maintained stable platelet counts.
  • ||||||||||  Mulpleta (lusutrombopag) / Shionogi, Doptelet (avatrombopag) / SOBI
    Prevention of bleeding related to invasive procedures in patients with cirrhosis (Gold Room) -  Mar 16, 2024 - Abstract #EASLILC2024EASL_ILC_80;    
    Future collaborative multicentre clinical research will bridge remaining knowledge gaps. In the meanwhile, hepatologists should work to promote guideline recommendations broadly among clinicians to improve and standardise care of patients with cirrhosis.
  • ||||||||||  Doptelet (avatrombopag) / SOBI
    Journal:  Avatrombopag Induced Thrombocytosis with Transient Ischemic Like Events. (Pubmed Central) -  Jan 27, 2024   
    Among the 27 patients, 15 patients received MSCs combined with avatrombopag regimens, 8 patients received MSCs combined with herombopag regimens, 4 patients received MSCs combined with eltrombopa regimens, 22 patients (78.6%) had complete response (CR, defined as PLT?50 No abstract available
  • ||||||||||  Mulpleta (lusutrombopag) / Shionogi, Doptelet (avatrombopag) / SOBI
    Journal:  Knowledge map of thrombopoietin receptor agonists: A bibliometric analysis. (Pubmed Central) -  Jan 25, 2024   
    When author keywords were categorised into three clusters, i.e., cluster 1 (immune thrombocytopenic purpura (ITP)), cluster 2 (avatrombopag, lusutrombopag, and thrombocytopenia), and cluster 3 (TPO-RAs for ITP and off-label drug use), ITP was found to be the current research hotspot, while oral TPO-RAs and licensed or unlicensed drug indications of thrombocytopenic diseases require further investigation. This study has generated the knowledge map of TPO-RAs, which provides a dynamic roadmap for future research in this field.
  • ||||||||||  Doptelet (avatrombopag) / SOBI
    Observational data, Journal:  Avatrombopag for adults with early versus chronic immune thrombocytopenia. (Pubmed Central) -  Jan 22, 2024   
    No other drug-related adverse events occurred in either group. Avatrombopag was safe and effective in patients with newly diagnosed and persistent ITP, with outcomes numerically, statistically, and clinically similar to patients receiving avatrombopag for chronic ITP.
  • ||||||||||  Nplate (romiplostim) / Amgen, Kyowa Kirin, Doptelet (avatrombopag) / SOBI
    Review, Journal:  Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists. (Pubmed Central) -  Nov 4, 2023   
    When employed in the appropriate patient population and used properly, TPO-RAs can successfully and safely manage CIT for extended periods of time with minimal apparent risks. This comprehensive review discusses the evidence for TPO-RAs in CIT in patients with solid tumors, provides detailed guidance for their use in the clinic, and discusses ongoing essential clinical trials in management of CIT.
  • ||||||||||  Doptelet (avatrombopag) / SOBI
    Avatrombopag in Combination with Immunosuppressive Therapy for Hepatitis-Associated Aplastic Anemia (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_5516;    
    Recent studies have shown that adding thrombopoietin receptor agonist (TPO-RA) eltrombopag to standard IST can lead to a more, faster, and better hematologic responses...Avatrombopag was incorporated into day 1 of standard immunosuppressive therapy with p-ATG and cyclosporine for all the eight HAAA patients...There is no clonal evolution, i.e., MDS, AML, and PNH, was observed. In conclusion, avatrombopag may be used as a safe and effective TPO-RA, added to IST for the treatment of hepatitis-associated aplastic anemia, which maybe improve the efficacy and the strength of hematologic response in HAAA.
  • ||||||||||  Doptelet (avatrombopag) / SOBI
    Avatrombopag Is Effective in First-Line Treatment of Severe Aplastic Anemia: Early Outcomes of a Prospective Study (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_5512;    
    P2
    Antithymocyte globulin (ATG) and cyclosporine based immunosuppressive therapy (IST) is effective for patients not eligible for hematopoietic stem cell transplant, and the response rate is 60-70%...Thrombopoietin receptor agonist (TPO-RA) eltrombopag improves the overall response (OR) rate and CR rate of SAA patients when combined with IST, but its hepatotoxicity is still worrying...One patient evolved to hemolytic paroxysmal nocturnal hemoglobinuria at 3 months, with normal count of platelet and white blood cell. In conclusion, the addition of avatrombopag to IST as first-line treatment showed earlier hematologic response and higher complete response rate for patients with SAA.
  • ||||||||||  Nplate (romiplostim) / Amgen, Kyowa Kirin, Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis
    Interim Analysis of Treatment Satisfaction from a Prospective Phase 4 Study in Adult Immune Thrombocytopenia (ITP) Subjects after Switching from Eltrombopag or Romiplostim to Avatrombopag (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_5370;    
    P4
    Despite high patient satisfaction scores at BL from prior therapy (ELT or ROMI), patients reported higher satisfaction following a switch to AVA across all domains of the TSQM (effectiveness, side effects, convenience, and global satisfaction) over 90 days. In a population of patients who were generally responding to TPO-RAs prior to a switch to AVA, mean/median PCs were also either improved or maintained with AVA treatment for the duration of the study (reported in a separate abstract submission), suggesting that some patients may experience sustained effectiveness paired with enhanced overall treatment satisfaction when switching from ELT or ROMI.
  • ||||||||||  Doptelet (avatrombopag) / SOBI
    Avatrombopag for Adults with Early Versus Chronic Immune Thrombocytopenia (SDCC - Room 30) -  Nov 3, 2023 - Abstract #ASH2023ASH_3001;    
    Given its lack of dietary restrictions and hepatotoxicity, access to AVA in early ITP could improve disease outcomes and patient health-related quality of life. Further studies are needed to confirm our findings and evaluate the ability of AVA to induce sustained responses off treatment in patients with early ITP.